The 2015 iCMLf Goldman Prize is awarded to Professor Michele Baccarani

The annual Goldman Prize awarded by the iCMLf in honour of Professor John Goldman complements the iCMLf’s Rowley Prize as a clinical equivalent recognising outstanding lifetime contributions to the management of patients with CML. The iCMLf awards the 2015 Goldman Prize to Professor Michele Baccarani in recognition of his over forty years of dedication to clinical excellence in the management of CML.  

“I did not give any personal contribution to the development of tyrosine kinase inhibitors, but contributed to the best of my abilities to the introduction and clinical application of TKI’s”, he explains. Professor Baccarani has conducted many Phase I, II and III studies to evaluate the efficacy and safety of tyrosine kinase inhibitors and furthered the understanding of their proper use in clinical practice by developing internationally recognised guidelines and recommendations.

Dr. Michele Baccarani was Professor of Haematology at the University of Bologna and Head of the Department of Haematology and Oncology "L. and A. Seràgnoli" at the S. Orsola-Malpighi University Hospital, Bologna until November 2012. Since 1989, he has served as the Chairman of the GIMEMA CML Working Party (formerly the Italian Cooperative Study Group on Chronic Myeloid Leukaemia). He is Past-President of both the Italian Society of Haematology and the Italian Society of Experimental Haematology. Professor Baccarani headed the Division of Haematology and Bone Marrow Transplantation of Udine University Hospital during his post as a Professor of Haematology at Udine University. He has also held faculty positions as a Professor of Haematology at Trieste University and of Cancer Chemotherapy at Chieti University. Professor Baccarani is first or contributing author on over 500 publications in the field of hematology.

Michele Baccarani's clinical interests include chronic myeloid leukemia, acute leukemia, chemotherapy and stem cell transplantation. His research interests focus on stem cell, multi-drug resistance and molecular pathogenesis of leukemia.